SC66

SKU: orb1304506

Description

SC66 is a potent and selective AKT inhibitor, demonstrating activity in hepatocellular carcinoma cell lines including HepG2, HA22T/VGH, and PLC/PRF/5 with an IC50 of approximately 0.75 µg/ml at 72 hours. This small molecule is a valuable research tool for studying the PI3K/AKT signaling pathway in cancer biology, applicable in both in vitro and in vivo experimental models.

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 871361-88-5
• MW: 276.33
• Purity: 99.60% (May vary between batches)
• Formula: C₁₈H₁₆N₂O
• SMILES: O=C1\C(CCC\C1=C/c1ccncc1)=C\c1ccncc1
• Target: Apoptosis|||Akt
• Solubility: DMSO:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  Akt:0.75 μg/ml
• In Vivo:
  In xenograft models, SC66 can inhibit tumor growth of Hep3B cells.
• In Vitro:
  HepG2, HA22T/VGH, and PLC/PRF/5 cells had similar IC50 values of approximately 0.85 and 0.75 μg/ml at 48 and 72 hours for SC66, respectively. The most resistant cell line was Huh7(IC50: 3.1/2.8 μg/ml, at 48/72 h), while the Hep3B cell line was found to be the most sensitive, (IC50: 0.75/0.5 μg/ml, at 48/72 h). SC66 reduced cell viability in a time- and dose-dependent manner inhibited colony formation and induced apoptosis in HCC cells. SC66 treatment led to a reduction in total and phospho-AKT levels. In addition, SC66 induces the production of reactive oxygen species (ROS) and DNA damage. SC66 significantly potentiates the effects of both conventional chemotherapeutic and targeted agents, doxorubicin and everolimus, respectively.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Apoptosis, Akt, inhibit, Inhibitor, SC 66, SC66, SC-66, PKB, Protein kinase B

Compound Identifiers

PubChem CID

6018993